WallStSmart

Dynavax Technologies Corporation (DVAX)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 5149% more annual revenue ($17.35B vs $330.51M). TEVA leads profitability with a 9.0% profit margin vs -0.1%. TEVA earns a higher WallStSmart Score of 62/100 (C+).

DVAX

Hold

45

out of 100

Grade: D+

Growth: 3.3Profit: 3.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.98

TEVA

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DVAX.

TEVAUndervalued (+46.3%)

Margin of Safety

+46.3%

Fair Value

$63.92

Current Price

$35.73

$28.19 discount

UndervaluedFair: $63.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVAX0 strengths · Avg: 0/10

No standout strengths identified

TEVA2 strengths · Avg: 9.5/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

Return on EquityProfitability
21.6%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

DVAX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

EPS GrowthGrowth
0.7%4/10

0.7% earnings growth

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.2%3/10

Operating margin of 0.2%

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
26.9x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DVAX

DVAX has a balanced fundamental profile.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, Return on Equity.

Bear Case : DVAX

The primary concerns for DVAX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.

Key Dynamics to Monitor

DVAX profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

DVAX carries more volatility with a beta of 0.93 — expect wider price swings.

TEVA is growing revenue faster at 2.3% — sustainability is the question.

DVAX generates stronger free cash flow (33M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (62/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dynavax Technologies Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?